Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

NCT05388500 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

800

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Paclitaxel + Trastuzumab
DRUG: Trastuzumab

Sponsor

Institut de cancérologie Strasbourg Europe